BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05516758 (Peresolimab in Rheumatoid Arthritis): BVCT ex-ante prediction vs. reported outcome

On 26 Nov 2022, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 30 Oct 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05516758
Acronym
RESOLUTION-1
Drug Name
Peresolimab
Drug MoA
PD1 agonist
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Immune System Diseases
Indication
Rheumatoid Arthritis
Human Patients
491
Sponsor
Eli Lilly and Company
Phase
Phase 2

Prediction of , index 711

Prospective Prediction
Prediction Index
711
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
FAILURE (statistically insignificant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
704 days in advance
Readout Data Interpretation
peresolimab terminated without data disclosure despite positive phase2a data in 2023 (see add'l link below)
Press Release
Additional Readout Data
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
Phase
Phase 2
Status
Terminated
Enrollment
491
Lead sponsor
Eli Lilly and Company
Conditions
Rheumatoid Arthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases
Interventions
DRUG: Peresolimab; DRUG: Placebo
Design
Randomized · Parallel · Double
Primary purpose
Treatment
Start
2022-08-31
Primary completion
2023-11-20
Completion
2025-01-17
Results first posted
2025-12-04
Primary outcomes
  • Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20) Response at Week 12 (Week 12)

NCT05516758 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials